PDF(Pubmed)
Abstract：
OBJECTIVE: Thromboembolism complication is considered the most common complication associated with the treatment of endovascular. This systematic review and meta-analysis aimed to assess the studies investigating the effect of glycoprotein IIb/IIIa inhibitor agents on thromboembolic complications during endovascular aneurysm coiling.
METHODS: This systematic review investigated the outcome of the use of three glycoprotein IIb/IIIa inhibitor agents (ie abciximab, tirofiban, and eptifibatide) on the thromboembolic complications during endovascular aneurysm coiling. The electronic databases of PubMed, Web of Science, Scopus, and Medline were searched up to 25 June 2021, using the keywords \"Abciximab,\" \"Tirofiban,\" and \"Eptifibatide\" incombination with \"Thromboembolism Complication,\" \"Aneurysms,\" and \"Endovascular Aneurysm Coiling.\"
RESULTS: A total of 21 articles were found to be eligible and included in this review. The rates of complete and partial recanalization were estimated to be 56% and 92% in patients who underwent abciximab and tirofiban therapy, respectively. Rupture aneurysms were found in the majority of patients. In general, the mortality rate of the patients treated for thromboembolic complications during endovascular treatment of cerebral aneurysms with glycoprotein IIb/IIIa inhibitors was found to be 4.8% (CI 95%:0.027-0.067; p < .005). The average remission rate in studies investigating thromboembolism was 91% (CI 95%:0.88-0.95, I2 : 65.65/p < .001).
CONCLUSIONS: Based on the obtained results, a higher mean rate of complete recanalization by eptifibatide was found in studies in which abciximab or tirofiban were used, compared to other mentioned agents. Moreover, the amount of hemorrhage was reported to be less after using tirofiban rather than abciximab.
METHODS: This systematic review investigated the outcome of the use of three glycoprotein IIb/IIIa inhibitor agents (ie abciximab, tirofiban, and eptifibatide) on the thromboembolic complications during endovascular aneurysm coiling. The electronic databases of PubMed, Web of Science, Scopus, and Medline were searched up to 25 June 2021, using the keywords \"Abciximab,\" \"Tirofiban,\" and \"Eptifibatide\" incombination with \"Thromboembolism Complication,\" \"Aneurysms,\" and \"Endovascular Aneurysm Coiling.\"
RESULTS: A total of 21 articles were found to be eligible and included in this review. The rates of complete and partial recanalization were estimated to be 56% and 92% in patients who underwent abciximab and tirofiban therapy, respectively. Rupture aneurysms were found in the majority of patients. In general, the mortality rate of the patients treated for thromboembolic complications during endovascular treatment of cerebral aneurysms with glycoprotein IIb/IIIa inhibitors was found to be 4.8% (CI 95%:0.027-0.067; p < .005). The average remission rate in studies investigating thromboembolism was 91% (CI 95%:0.88-0.95, I2 : 65.65/p < .001).
CONCLUSIONS: Based on the obtained results, a higher mean rate of complete recanalization by eptifibatide was found in studies in which abciximab or tirofiban were used, compared to other mentioned agents. Moreover, the amount of hemorrhage was reported to be less after using tirofiban rather than abciximab.
摘要：
目的：血栓栓塞并发症被认为是血管内治疗最常见的并发症。本系统综述和荟萃分析旨在评估研究糖蛋白IIb/IIIa抑制剂对血管内动脉瘤卷曲过程中血栓栓塞并发症的影响的研究。
方法：本系统综述调查了使用三种糖蛋白IIb/IIIa抑制剂（即abciximab，替罗非班,和eptifibatide）对血管内动脉瘤盘绕过程中的血栓栓塞并发症。PubMed的电子数据库，WebofScience,Scopus,和Medline在2021年6月25日之前使用关键字\“Abciximab，\"\"替罗非班,\"和\"依替巴肽\"与\"血栓栓塞并发症,\"\"动脉瘤,“和”血管内动脉瘤盘绕。\"
结果：共有21篇文章被认为是合格的，并纳入本综述。在接受阿西昔单抗和替罗非班治疗的患者中，估计完全和部分再通率分别为56％和92％。分别。在大多数患者中发现破裂动脉瘤。总的来说,发现在使用糖蛋白IIb/IIIa抑制剂的脑动脉瘤血管内治疗期间,血栓栓塞并发症患者的死亡率为4.8%(CI95%:0.027~0.067;p<.005).研究血栓栓塞的平均缓解率为91%(CI95%:0.88-0.95,I2:65.65/p<.001)。
结论：根据获得的结果，在使用阿昔单抗或替罗非班的研究中，发现依替巴肽完全再通的平均比率较高，与其他提到的代理商相比。此外，据报道,使用替罗非班而非阿西昔单抗后,出血量较少.
方法：本系统综述调查了使用三种糖蛋白IIb/IIIa抑制剂（即abciximab，替罗非班,和eptifibatide）对血管内动脉瘤盘绕过程中的血栓栓塞并发症。PubMed的电子数据库，WebofScience,Scopus,和Medline在2021年6月25日之前使用关键字\“Abciximab，\"\"替罗非班,\"和\"依替巴肽\"与\"血栓栓塞并发症,\"\"动脉瘤,“和”血管内动脉瘤盘绕。\"
结果：共有21篇文章被认为是合格的，并纳入本综述。在接受阿西昔单抗和替罗非班治疗的患者中，估计完全和部分再通率分别为56％和92％。分别。在大多数患者中发现破裂动脉瘤。总的来说,发现在使用糖蛋白IIb/IIIa抑制剂的脑动脉瘤血管内治疗期间,血栓栓塞并发症患者的死亡率为4.8%(CI95%:0.027~0.067;p<.005).研究血栓栓塞的平均缓解率为91%(CI95%:0.88-0.95,I2:65.65/p<.001)。
结论：根据获得的结果，在使用阿昔单抗或替罗非班的研究中，发现依替巴肽完全再通的平均比率较高，与其他提到的代理商相比。此外，据报道,使用替罗非班而非阿西昔单抗后,出血量较少.
